Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy

Bioengineered

Volumn 4, Issue 2, 2013, Pages 84-89

  Gentschev, Ivaylo ^a,b   Patil, Sandeep S ^b   Adelfinger, Marion ^b   Weibel, Stephanie ^b   Geissinger, Ulrike ^a   Frentzen, Alexa ^a   Chen, Nanhai G ^a,c   Yu, Yong A ^a,c   Zhang, Qian ^a,c   Ogilvie, Gregory ^c,d   Szalay, Aladar A ^a,b,c,e  

^a GENELUX CORPORATION   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d California Veterinary Specialists   (United States)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cancer; Canine cancer therapy; Canine xenografts; Oncolysis; Oncolytic virus

Indexed keywords

CD11B ANTIGEN; CD45 ANTIGEN; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CANINE CANCER; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FLOW CYTOMETRY; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MELANOMA; MICROSCOPY; MOUSE; MOUTH CANCER; NONHUMAN; OSTEOSARCOMA; PROSTATE CARCINOMA; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; TUMOR GROWTH; TUMOR XENOGRAFT; VIRUS CHARACTERIZATION; VIRUS CULTURE; VIRUS REPLICATION; ANIMAL; CANINE CANCER THERAPY; CANINE XENOGRAFTS; DOG; DRUG SCREENING; GENETICS; METHODOLOGY; NEOPLASM; ONCOLYSIS; ONCOLYTIC VIROTHERAPY; PHYSIOLOGY; VACCINIA VIRUS;

CANCER; CANINE CANCER THERAPY; CANINE XENOGRAFTS; ONCOLYSIS; ONCOLYTIC VIRUS;

ANIMALS; DOGS; MICE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VACCINIA VIRUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877710371     PISSN: 19491018     EISSN: 19491026     Source Type: Journal    
DOI: 10.4161/bioe.22462     Document Type: Article

References (20)

1. Merlo DF, Rossi L, Pellegrino C, Ceppi M, Cardellino U, Capurro C, et al. Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. J Vet Intern Med 2008; 22:976-84; PMID:18564221; http://dx.doi.org/10.1111/j.1939-1676.2008.0133.x.
2. Kelsey JL, Moore AS, Glickman LT. Epidemiologic studies of risk factors for cancer in pet dogs. Epidemiol Rev 1998; 20:204-17; PMID:9919439; http://dx.doi. org/10.1093/oxfordjournals.epirev.a017981.
3. Ternovoi VV, Le LP, Belousova N, Smith BF, Siegal GP, Curiel DT. Productive replication of human adenovirus type 5 in canine cells. J Virol 2005; 79:1308-11; PMID:15613357; http://dx.doi.org/10.1128/JVI.79.2.1308-1311.2005.
4. Smith BF, Curiel DT, Ternovoi VV, Borovjagin AV, Baker HJ, Cox N, et al. Administration of a conditionally replicative oncolytic canine adenovirus in normal dogs. Cancer Biother Radiopharm 2006; 21:601-6; PMID:17257075; http://dx.doi.org/10.1089/cbr.2006.21.601.
5. Le LP, Rivera AA, Glasgow JN, Ternovoi VV, Wu H, Wang M, et al. Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells. Gene Ther 2006; 13:389-99; PMID:16292351; http://dx.doi. org/10.1038/sj.gt.3302674.
6. Suter SE, Chein MB, von Messling V, Yip B, Cattaneo R, Vernau W, et al. In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma. Clin Cancer Res 2005; 11:1579-87; PMID:15746063; http://dx.doi. org/10.1158/1078-0432.CCR-04-1944.
7. Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, Chen N, et al. Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68. J Oncol 2010; 2010:736907; PMID:20631910; http://dx.doi. org/10.1155/2010/736907.
8. Gentschev I, Stritzker J, Hofmann E, Weibel S, Yu YA, Chen N, et al. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent. Cancer Gene Ther 2009; 16:320-8; PMID:18949014; http://dx.doi.org/10.1038/cgt.2008.87.
9. Gentschev I, Müller M, Adelfinger M, Weibel S, Grummt F, Zimmermann M, et al. Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68. PLoS One 2011; 6:e22069; PMID:21779374; http://dx.doi.org/10.1371/journal.pone.0022069.
10. Patil SS, Gentschev I, Adelfinger M, Donat U, Hess M, Weibel S, et al. Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody. PLoS One 2012:e47472; PMID:23091626; http://dx.doi.org/10.1371/journal. pone.0047472.
11. Arendt M, Nasir L, Morgan IM. Oncolytic gene therapy for canine cancers: teaching old dog viruses new tricks. Vet Comp Oncol 2009; 7:153-61; PMID:19691644; http://dx.doi.org/10.1111/j.1476-5829.2009.00187.x.
12. Patil SS, Gentschev I, Nolte I, Ogilvie G, Szalay AA. Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients. J Transl Med 2012; 10:3; PMID:22216938; http://dx.doi. org/10.1186/1479-5876-10-3.
13. Gil M, Bieniasz M, Seshadri M, Fisher D, Ciesielski MJ, Chen Y, et al. Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice. Br J Cancer 2011; 105:1512-21; PMID:21989183; http://dx.doi. org/10.1038/bjc.2011.429.
14. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007; 15:1686-93; PMID:17579581; http://dx.doi.org/10.1038/sj.mt.6300215.
15. Gentschev I, Adelfinger M, Josupeit R, Rudolph S, Ehrig K, Donat U, et al. Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. PLoS One 2012; 7:e37239; PMID:22615950; http://dx.doi.org/10.1371/journal.pone.0037239.
16. Reimann-Berg N, Willenbrock S, Murua Escobar H, Eberle N, Gerhauser I, Mischke R, et al. Two new cases of polysomy 13 in canine prostate cancer. Cytogenet Genome Res 2011; 132:16-21; PMID:20668368; http://dx.doi.org/10.1159/000317077.
17. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 2007; 67:10038-46; PMID:17942938; http://dx.doi. org/10.1158/0008-5472.CAN-07-0146.
18. Gentschev I, Donat U, Hofmann E, Weibel S, Adelfinger M, Raab V, et al. Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68. J Biomed Biotechnol 2010; 2010:489759; PMID:20379368; http://dx.doi. org/10.1155/2010/489759.
19. Weibel S, Stritzker J, Eck M, Goebel W, Szalay AA. Colonization of experimental murine breast tumours by Escherichia coli K-12 significantly alters the tumour microenvironment. Cell Microbiol 2008; 10:1235-48; PMID:18208564; http://dx.doi.org/10.1111/j.1462-5822.2008.01122.x.
20. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22:238-44; PMID:20171075; http://dx.doi.org/10.1016/j.coi.2010.01.021.